Stockholders' Equity (Details Narrative) - USD ($)			1 Months Ended				3 Months Ended	6 Months Ended
	Sep. 12, 2019	Jan. 07, 2019	Feb. 24, 2020	Feb. 18, 2020	Nov. 25, 2019	Aug. 31, 2019	Jan. 31, 2020	Jan. 31, 2020	Feb. 14, 2020	Jul. 31, 2019
Common stock payable, Shares								436,120
Common stock payable, Amount								$ 86,239
Common stock issued							281,810	281,810
Stock Issued During Period, Shares Issued for Services							560,000
Stock Issued During Period, Value, Issued for Services							$ 243,600	$ 243,600
Common stock issued for conversion debt, Shares							308,000	5,006,548
Common stock issued for conversion debt, Value							$ 141,990	$ 2,904,758
Cancellation of common stock	20,375,900
Common stock, shares outstanding							69,129,001	69,129,001		78,608,419
Equity Purchase Agreement [Member] | Investors
Common stock purchased					$ 40,000,000
Number of common stock issued					1,719,901
Regentys
LOI Terms		Pursuant to the Company’s acquisition of Regentys on January 7, 2019 to acquire a 51% interest, the Company was issued 12,048,161 shares of Regentys common stock. As of January 31, 2020, Regentys had a total of 18,623,278 shares of common stock and 2,793,192 Series A voting preferred stock for a total of 21,416,470 total voting shares outstanding. As such, there are 9,368,309 of shares that belong to non-controlling interest shareholders which represents a 43.74% non-controlling interest.
Olaregen
LOI Terms		Pursuant to the Company’s acquisition of Olaregen on January 7, 2019 to acquire a 51% interest, the Company was issued 3,282,632 shares of Olaregen common stock. In May 2019, the Company issued 4,000,000 shares of common stock contributed and provided by the Friends of Generex Trust and a $2 million note payable for the acquisition of 592,683 shares of Series A Preferred Stock of Olaregen pursuant to a Stock Purchase Agreement entered into January 14, 2019 subject to the approval of the Board of Directors of Olaregen and consummated on May 10, 2019. On August 16, 2019, the Company entered into a Share Exchange Agreement to purchase an additional 900,000 shares of common stock in Olaregen from other shareholders of Olaregen in exchange for 1,905,912 shares of Generex common stock and 476,478 shares of Antigen common stock. In September 2019, the Company converted all of the Series A Preferred Stock of Olaregen into common stock of Olaregen.
Common stock, shares outstanding							6,236,390	6,236,390	5,950,000
Preferred stock, shares outstanding							0	0
Non-controlling interest							1,461,075	1,461,075
Percentage of non-controlling interest							23.43%	23.43%
Medisource
Common stock issued for acquisition						400,000
Stock Price						$ 2.50
Pantheon [Member]
Common stock issued for acquisition						560,000
Stock Price						$ 2.50
NGIO
Common stock, shares outstanding									2,765,000
Subsequent Event [Member]
Stock Split			1.4:1
Number of common stock issued				26,806,714